Letters To The Editor Open Access
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Oct 15, 2016; 7(18): 481-482
Published online Oct 15, 2016. doi: 10.4239/wjd.v7.i18.481
Response to comment on: Statin use and risk of diabetes mellitus
Bharti Chogtu, Kurady Laxminarayana Bairy, Department of Pharmacology, Kasturba Medical College, Manipal University, Manipal 576104, Karnataka, India
Rahul Magazine, Department of Pulmonary Medicine, Kasturba Medical College, Manipal University, Manipal 576104, Karnataka, India
Author contributions: Chogtu B wrote this letter; Magazine R revised the letter; Bairy KL edited the letter.
Conflict-of-interest statement: The authors declare that they don’t have any conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Bharti Chogtu, MD, Associate Professor, Department of Pharmacology, Kasturba Medical College, Manipal University, SH 65, Madhav Nagar, Manipal 576104, Karnataka, India. bhartimagazine@gmail.com
Telephone: +91-0820-2922582
Received: May 19, 2016
Peer-review started: May 20, 2016
First decision: July 4, 2016
Revised: July 28, 2016
Accepted: August 17, 2016
Article in press: August 18, 2016
Published online: October 15, 2016
Processing time: 144 Days and 22.7 Hours

Abstract

In letter to the editor “Comment on: Statin use and risk of diabetes mellitus” authors found the statement “pravastatin 40 mg/d reduced the risk of diabetes by 30% in West of Scotland Coronary Prevention study” erroneous. As per our opinion the statement is right but had been referenced incorrectly.

Key Words: Pravastatin; Diabetes mellitus

Core tip: The statement “Pravastatin has shown to decrease the risk of developing diabetes by 30%” is correct and had been wrongly referenced in “Statin use and risk of diabetes mellitus” by Chogtu et al.
TO THE EDITOR

We thank Eren et al for showing interest in the review article “statin use and risk of diabetes mellitus”[1]. Eren et al[2] have pointed to an apparent factual error in the following statement: “pravastatin 40 mg/d reduced the risk of diabetes by 30% in West of Scotland Coronary Prevention study (WOSCOPS)”. However, in our opinion, this statement is correct if we refer to WOSCOPS 2001, in which authors have put forth that pravastatin in a dose of 40 mg/d resulted in a 30% reduction (P = 0.042) in the risk of diabetes[3]. Haffner[4] in an editorial in the same issue of Circulation has also alluded to the fact that Pravastatin reduced incidence of diabetes by 30% - though with a caveat that these results should be cautiously interpreted as the statistical significance in WOSCOPS 2001 was modest.

Regarding the review article “Statin use and risk of diabetes mellitus” the error is not in the statement but in quoting the reference. We should have referenced it as Freeman et al[3] rather than Kotseva et al[5]. We again thank Eren et al[2] to bring this error to our notice.

Footnotes

Manuscript source: Unsolicited manuscript

Specialty type: Endocrinology and metabolism

Country of origin: India

Peer-review report classification

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

P- Reviewer: Beltowski J, Cheng JT, Kawasaki EN, Tarantino G S- Editor: Gong XM L- Editor: A E- Editor: Li D

References
1.  Chogtu B, Magazine R, Bairy KL. Statin use and risk of diabetes mellitus. World J Diabetes. 2015;6:352-357.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in CrossRef: 41]  [Cited by in F6Publishing: 42]  [Article Influence: 4.7]  [Reference Citation Analysis (0)]
2.  Eren MA, Sabuncu T, Karaaslan H. Comment on: Statin use and risk of diabetes mellitus. World J Diabetes. 2016;7:175-176.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 1]  [Reference Citation Analysis (0)]
3.  Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103:357-362.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 613]  [Cited by in F6Publishing: 582]  [Article Influence: 25.3]  [Reference Citation Analysis (0)]
4.  Haffner SM. Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors. Circulation. 2001;103:346-347.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 16]  [Cited by in F6Publishing: 16]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]
5.  Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373:929-940.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 602]  [Cited by in F6Publishing: 618]  [Article Influence: 41.2]  [Reference Citation Analysis (0)]